Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02569489
Recruitment Status : Withdrawn (Reconsideration of Study Design; plan for alternative protocol)
First Posted : October 6, 2015
Last Update Posted : June 10, 2016
Sponsor:
Information provided by (Responsible Party):
HUYA Bioscience International

Brief Summary:
This is a phase I multi-center dose escalation study of the histone deacetylase inhibitor (HDACi) HBI-8000 when given in combination with paclitaxel and trastuzumab in women with advanced or metastatic HER2+ breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: HBI-8000 Drug: Trastuzumab Drug: Paclitaxel Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
Study Start Date : December 2015
Actual Primary Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: HBI-8000, Paclitaxel, Trastuzumab
HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
Drug: HBI-8000
Drug: Trastuzumab
Drug: Paclitaxel



Primary Outcome Measures :
  1. MTD of HBI-8000 twice weekly in combination with weekly paclitaxel and trastuzumab in women with HER2+ breast cancer [ Time Frame: 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female subject, age ≥18 years at the time of signing informed consent
  2. Histologically or cytologically confirmed adenocarcinoma of breast, HER2+ as determined by FISH or IHC
  3. Having received at least one prior systemic therapy with FDA approved agent(s) for metastatic disease and have no curative option
  4. Measureable disease as defined by RECIST 1.1
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  6. Laboratory parameters within 14 days prior to dosing:

    • Absolute neutrophil count (ANC) ≥ 1.5 X 109/L independent of growth factor support
    • Hemoglobin (Hgb) ≥9 gm/dL independent of transfusion or growth factor support
    • Platelets (plt) ≥ 100 x 109/L independent of transfusion or growth factor support
    • AST and ALT ≤2.5 x Upper Limit of Normal (ULN); if hepatic metastasis is present, ≤2.5 x ULN
    • Serum total bilirubin ≤ 1.5 x ULN; if with Gilbert's Syndrome, direct bilirubin must be normal
    • Serum creatinine ≤ 1.5 x ULN or eGFR ≥ 60ml/min
    • Serum albumin > 3.0 g/dL
    • Prothrombin time (PT)/International normalized ratio (INR) ≤ 1.5, partial thromboplastin time (PTT) within normal limits (WNL) of the institution
  7. Negative serum pregnancy test in subjects with child-bearing potential; and commit to abstinence or comply with medically proven contraception methods
  8. Agree to abstain from breast feeding from the start of study treatment and >28 days after the last dose of study drugs.
  9. Understand and voluntarily sign informed consent

Exclusion Criteria:

  1. Receiving chemotherapy, immunotherapy, biological, radiation therapy or investigational agent (therapeutic or diagnostic) within 4 weeks prior to receipt of study medication. Major surgery, other than diagnostic surgery, within 4 weeks before first study drug administration.
  2. Significant cardiac history:

    • History of myocardial infarction or ischemic heart disease within 1 year before the first study drug administration
    • Uncontrolled arrhythmia, such as ventricular tachycardia, ventricular fibrillation; second- or third-degree heart block; unstable angina, coronary angioplasty or stenting, or myocardial infarction (MI) within 6 months of study entry
    • History of congenital QT prolongation, or baseline QTcF > 470 ms using Fridericia's formula
    • ECG findings consistent with active ischemic heart disease
    • New York Heart Association Class III or IV cardiac disease
    • Left ventricular Ejection Fraction measuring ≥ 55% at baseline ECHO
    • Uncontrolled hypertension: blood pressure consistently greater than 150 mm Hg systolic and 100 mm Hg diastolic in spite of antihypertensive medication
  3. Patients with active brain metastasis or leptomeningeal involvement. Patients who have brain metastases that have been previously treated, who are asymptomatic, and whose lesions by imaging are at least stable and without interim development of new lesions for at least 6 weeks may be enrolled. Patients who require continued steroid therapy as management for their brain metastases are not eligible
  4. Persistent diarrhea or malabsorption NCI CTCAE (version 4.03) grade ≥ 1 despite medical management, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease or condition significantly affecting GI function
  5. Peripheral neuropathy NCI CTCAE (Version 4.03) Grade ≥ 2
  6. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  7. Known infection with human immunodeficiency virus (HIV) or active hepatitis A, B, or C.
  8. Patients with a prior hypersensitivity reaction to any product containing polyvinylpyrrolidone, microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, talc or magnesium stearate.
  9. Second malignancy unless in remission for > 5 years. (Non-melanoma skin cancer or carcinoma in situ of the cervix treated with curative intent is not exclusionary.)
  10. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient. Examples of such conditions include infection requiring parenteral anti-infective treatment, hydronephrosis, liver failure, any altered mental status or any psychiatric condition that would interfere with the understanding of the informed consent.
  11. Unwilling or unable to comply with procedures required in this protocol.

Layout table for additonal information
Responsible Party: HUYA Bioscience International
ClinicalTrials.gov Identifier: NCT02569489     History of Changes
Other Study ID Numbers: HBI-8000-106
First Posted: October 6, 2015    Key Record Dates
Last Update Posted: June 10, 2016
Last Verified: June 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Trastuzumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological